country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-162242

Copy Link Print Information

Cap-dependent endonuclease-IN-27

Cap-dependent endonuclease-IN-27 (Compound 8) is an orally active potent cap-dependent endonuclease (CEN) inhibitor. Cap-dependent endonuclease-IN-27, an antiviral agent, shows activity against influenza B virus. Cap-dependent endonuclease-IN-27 has inhibitory activity against IFV A/WSN/33 (H1N1) polymerase (EC₅₀ = 12.26 nM).

For research use only. We do not sell to patients.

CAS No.: 2741952-21-4
Formula: C₂₃H₁₉F₂N₃O₄
Molecular Weight:439.41

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (276 KB)

Cap-dependent endonuclease-IN-27 Chemical Structure

CAS No.: 2741952-21-4

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
Chemical Information
Protocols (1)
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	CC₅₀	13.3 μM Compound: 8	Cytotoxicity against human A-375 cells incubated for 3 days by CellTiter-Glo assay Cytotoxicity against human A-375 cells incubated for 3 days by CellTiter-Glo assay	[PMID: 38301207]
CCRF-CEM	CC₅₀	6.48 μM Compound: 8	Cytotoxicity against human CCRF-CEM cells incubated for 3 days by CellTiter-Glo assay Cytotoxicity against human CCRF-CEM cells incubated for 3 days by CellTiter-Glo assay	[PMID: 38301207]
COLO 205	CC₅₀	7.04 μM Compound: 8	Cytotoxicity against human COLO 205 cells incubated for 3 days by CellTiter-Glo assay Cytotoxicity against human COLO 205 cells incubated for 3 days by CellTiter-Glo assay	[PMID: 38301207]
H1-HeLa	CC₅₀	9.77 μM Compound: 8	Cytotoxicity against human H1-HeLa cells incubated for 3 days by CellTiter-Glo assay Cytotoxicity against human H1-HeLa cells incubated for 3 days by CellTiter-Glo assay	[PMID: 38301207]
HEK293	CC₅₀	20.3 μM Compound: 8	Cytotoxicity against HEK293 cells incubated for 3 days by CellTiter-Glo assay Cytotoxicity against HEK293 cells incubated for 3 days by CellTiter-Glo assay	[PMID: 38301207]
HEp-2	CC₅₀	12.45 μM Compound: 8	Cytotoxicity against human HEp-2 cells incubated for 3 days by CellTiter-Glo assay Cytotoxicity against human HEp-2 cells incubated for 3 days by CellTiter-Glo assay	[PMID: 38301207]
HepG2	CC₅₀	5.19 μM Compound: 8	Cytotoxicity against human HepG2 cells incubated for 3 days by CellTiter-Glo assay Cytotoxicity against human HepG2 cells incubated for 3 days by CellTiter-Glo assay	[PMID: 38301207]
MOLT-4	CC₅₀	4.13 μM Compound: 8	Cytotoxicity against human MOLT-4 cells incubated for 3 days by CellTiter-Glo assay Cytotoxicity against human MOLT-4 cells incubated for 3 days by CellTiter-Glo assay	[PMID: 38301207]
MRC5	CC₅₀	19.95 μM Compound: 8	Cytotoxicity against human MRC5 cells incubated for 3 days by CellTiter-Glo assay Cytotoxicity against human MRC5 cells incubated for 3 days by CellTiter-Glo assay	[PMID: 38301207]

Chemical Information

CAS No. 2741952-21-4
Molecular Weight 439.41
Formula C₂₃H₁₉F₂N₃O₄
SMILES

O=C1N(C)[C@@]2([H])N(N3C1=C(O)C(C=C3)=O)[C@H](C4=CC=CC=C4)C5=CC(F)=C(F)C=C5OCC2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Protocols

All Signal Pathway Related

Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Feng J, et al. Discovery of a Macrocyclic Influenza Cap-Dependent Endonuclease Inhibitor. J Med Chem. 2024 Feb 22;67(4):2570-2583. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote